Biotech Startups

Berkeley Lights (now Bruker Cellular Analysis) develops the Beacon optofluidic system for single-cell functional analysis, enabling researchers to profile live single cells to discover therapeutic antibodies, interrogate T cells, identify cell therapies, and accelerate cell line development. Its platform serves biotech, pharma, and academic researchers across discovery, basic research, and translational research.

7 investors

Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers. Beyond oncology, it collaborates with pharmaceutical partners and academic groups to apply the technology to other therapeutic areas including anti-infective, cardiovascular, ophthalmology, dementia, CNS, neuromuscular and respiratory conditions.

7 investors

Biotia develops infectious disease diagnostics using clinical metagenomic next-generation sequencing paired with artificial intelligence, offering diagnostic tests and genomics software for patients, providers, and health systems managing challenging infections. Its products detect pathogens and antimicrobial resistance markers and support genomic surveillance and infection control.

7 investors

bit.bio is a synthetic biology company that engineers human induced pluripotent stem cells into defined cell types for research, drug discovery, and cell therapy applications. The company markets cells and disease models through its ioCells brand for use in biomedical research and therapeutic development.

7 investors

MIT is an educational and research institution in Cambridge, Massachusetts, pursuing teaching, research, and innovation across science, engineering, and other fields. It serves undergraduate and graduate students and maintains a global community of faculty and researchers.

7 investors

BridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.

7 investors

Cabinet provides a platform for retailers to build private-label OTC and Rx medicine programs, covering formulation, sustainable packaging, and supply chain execution, and connects manufacturers to demand. It offers medicines in multiple formats with capabilities like clean-label, third-party testing, and refillable plastic-free packaging.

7 investors

CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.

7 investors

Caribou Biosciences is a clinical-stage biopharmaceutical company developing CRISPR genome-editing therapies, including off-the-shelf CAR-T cell therapies for hematologic malignancies and armored cell therapies using its Cas12a chRDNA platform. The company licenses foundational CRISPR-Cas9 intellectual property and advances drug candidates for patients with devastating diseases.

7 investors

Cartography develops antibody-based cancer therapies using single-cell sequencing and computational biology to identify precise cellular targets. The company combines genomics data analysis with therapeutic design to create more targeted treatments for cancer patients.

7 investors

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders. It focuses on drug development for patients with these conditions.

7 investors

Change Foods uses precision fermentation with microbes to produce real dairy proteins, fats, and flavors without cows, then applies traditional cheesemaking techniques to make animal-free cheese that tastes, stretches, and melts like conventional dairy cheese. The company targets consumers seeking sustainable dairy alternatives.

7 investors

Clear Labs develops fully automated next-generation sequencing (NGS) platforms that process genomic data into insights for research and surveillance applications across infectious disease, food safety, and oncology. The company serves laboratories, food brands, healthcare systems, and diagnostic organizations.

7 investors

Click Therapeutics develops, validates, and commercializes software-based prescription medical treatments, including software-enhanced drug products that combine digital therapeutics with pharmacotherapy. It targets diseases through a platform-based approach applying neuroscience and neuromodulatory mechanisms for patients with unmet medical needs.

7 investors

Clora operates an AI-powered talent marketplace connecting biotech and pharma teams with 15,000+ vetted life sciences consultants across 300+ skillsets for fractional, on-demand engagements. The platform matches companies to experts across the discovery and development lifecycle and handles contracting, onboarding, and payments.

7 investors

Cofactor Genomics develops predictive diagnostics for cancer immunotherapy using RNA-expression models to characterize tumor microenvironments and predict patient response. The company serves oncology and precision medicine markets by enabling more accurate patient-to-therapy matching.

7 investors

Constructive Bio is a biotechnology company that rewrites the genetic code to give cells access to non-canonical amino acid building blocks, expanding the range of proteins that can be designed, engineered, and manufactured. Its platform aims to move novel molecules from research to industrial-scale production for applications ranging from medicines to advanced materials.

7 investors

Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications. Its pipeline includes a CRF2 peptide agonist and a vasopressin neutralizing antibody, and it uses patient stratification based on human evidence and disease biology.

7 investors

Curebase provides a software platform for clinical trial management, serving contract research coordinators and trial sites. The platform emphasizes modern technology, data integrity, and compliance for advancing medical research.

7 investors

Deepcell uses artificial intelligence and high-resolution imaging to analyze cell morphology for biological research and discovery. The company serves scientists and life science researchers across multiple biological domains.

7 investors

Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds. Its pipeline includes a Phase 2-ready asset and multiple preclinical programs targeting brain health and neuroplasticity.

7 investors

Dren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.

7 investors

Encoded develops gene therapies for neurological disorders through an integrated platform approach. The company focuses on translating discoveries from research through clinical development and commercialization.

7 investors

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders. Founded in 2019, it focuses on the neuroscience area to treat central nervous system conditions.

7 investors